Showing 1 - 5 results of 5 for search 'Ricardo Restrepo‐Jaramillo', query time: 0.03s Refine Results
  1. 1
    A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil

    A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil by Diane L. Zwicke, Ricardo Restrepo-Jaramillo, Hassan Alnuaimat, Kathryn Gordon, Meredith Broderick, Lisa D. Edwards, Andrew Allmon, Peter J. Leary

    Published 2021-03-01
    Get full text
    Article
  2. 2
    Differences in health policies for drug availability in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension across Latin America

    Differences in health policies for drug availability in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension across Latin America by Mauricio Orozco‐Levi, Jorge Cáneva, Caio Fernandes, Ricardo Restrepo‐Jaramillo, Nayeli Zayas, Rafael Conde, Mirta Diez, Carlos Jardim, Manuel C. Pacheco Gallego, Luciano Melatini, Héctor Valdéz, Tomás Pulido

    Published 2022-01-01
    Get full text
    Article
  3. 3
    Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

    Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies by Nick H. Kim, Kelly M. Chin, Vallerie V. McLaughlin, Hilary DuBrock, Ricardo Restrepo-Jaramillo, Zeenat Safdar, Gwen MacDonald, Nicolas Martin, Daniel Rosenberg, Maria Solonets, Richard Channick

    Published 2024-01-01
    Get full text
    Article
  4. 4
    BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension

    BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension by Leslie A. Spikes, Abubakr A. Bajwa, Charles D. Burger, Sapna V. Desai, Michael S. Eggert, Karim A. El‐Kersh, Micah R. Fisher, Shilpa Johri, Joanna M. Joly, Jinesh Mehta, Harold I. Palevsky, Gautam V. Ramani, Ricardo Restrepo‐Jaramillo, Sandeep Sahay, Trushil G. Shah, Chunqin Deng, Melissa Miceli, Peter Smith, Shelley M. Shapiro

    Published 2022-04-01
    Get full text
    Article
  5. 5
    Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat

    Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat by Franck F. Rahaghi, Vijay P. Balasubramanian, Robert C. Bourge, Charles D. Burger, Murali M. Chakinala, Michael S. Eggert, Jean M. Elwing, Jeremy Feldman, Christopher King, James R. Klinger, Stephen C. Mathai, John Wesley McConnell, Harold I. Palevsky, Ricardo Restrepo‐Jaramillo, Zeenat Safdar, Jeffrey S. Sager, Namita Sood, Roxana Sulica, R. James White, Nicholas S. Hill

    Published 2022-04-01
    Get full text
    Article

Search Tools: